Pakistan Pharmaceutical Market Overview 2017

Pakistan
Pharmaceutical
Market overview
MUHAMMAD ALI
Email:phr_ali91@hotmail.com

phr_ali91@hotmail.com
Content
Global Pharmaceuticals Key Numbers
Pakistan Age structure, Economy
Pakistan Pharmaceutical Key Numbers
Pakistan Healthcare
 Pakistan Burden of Disease
 Pakistan Healthcare Structure
 Pakistan Healthcare Workforce
 Pakistan Healthcare Distribution system
Pakistan Leading Pharmaceuticals
Leading Therapeutic class
Leading Molecules
Leadings Brands
Product & Price
Pakistan Pharma Import & Export Partners
Pakistani Pharma Achievements
MUHAMMAD ALI 2

Global Key Numbers
Global medicine spending will reach nearly $1.5 trillion by 2021
Growth will slow from nearly 9% in 2014 and 2015 to 4–7% over the next five years
The U.S. will continue as the world’s largest pharmaceutical market and pharma emerging
markets will make up 9 of the top 20 markets with China as #2
QuintilesIMS
MUHAMMAD ALI 3

phr_ali91@hotmail.com MUHAMMAD ALI 4
Source: IMS Market Prognosis, Sept 2016; QuintilesIMS Institute, Oct 2016
Global Market Spending and Growth 2007–2021

Source: IMS Market Prognosis, Sept 2016; QuintilesIMS Institute, Oct 2016

Source: IMS Therapy Prognosis, Sept 2016; QuintilesIMS Institute, Oct 2016

https://igeahub.com/perspectives/companies/

https://igeahub.com/perspectives/product/

Pakistan
MUHAMMAD ALI 9
o Officially Name Islamic Republic of Pakistan
o Capital Islamabad
o National languages Urdu
o Currency Pakistani rupee (₨) (PKR)
o Provinces : 4
Area: 796,095 sq km
Location:
Southern Asia, bordering the Arabian Sea, between India on the east
and Iran and Afghanistan on the west and China in the north
Time difference: UTC+5

Pakistan
Population:
204,924,861 (July 2017 est.)
Age structure:
 0-14 years: 31.36% (male 33,005,623/female
31,265,463)
20,980,455)
36,907,683)
5,669,495)
 65 years and over: 4.48% (male
4,261,917/female 4,910,094) (2017 est.)
Population growth rate:
1.4% (2017 est.)
Death rate:
6.3 deaths/1,000 population (2017 est.)
Life expectancy at birth:
 total population: 67.7 years
 male: 65.8 years
 female: 69.8 years (2016 est.)
MUHAMMAD ALI 10

Pakistan Economy
GDP (purchasing power parity): $1.056 trillion (2017 est.)
GDP (official exchange rate): $278.9 billion (2015 est.)
GDP - real growth rate: 5.3% (2017 est.)
GDP - per capita (PPP): $5,400 (2017 est.)
Industrial production growth rate: 5% (2017 est.)
Inflation rate (consumer prices): 4.1% (2017 est.)
Exports: $21.7 billion (2017 est.)
Imports: $48.21 billion (2017 est.)
Budget:
 Revenues: $45.64 billion
 Expenditures : $59.28 billion
Exchange rates: Pakistani rupees (PKR) per US dollar -105 (FY2017 est.)
MUHAMMAD ALI 11

Pakistan Pharmaceutical Overview
Total Registered Pharmaceutical in Pakistan approximately 775
Multinational Pharmaceutical Company 26
National Pharmaceutical Company 749
Estimated size of the Pharmaceutical market is Pkr 343 Billion (IMS Q4, 2017)
Projected Growth of Market is 11.42% in 2018
Molecules 2,200 plus
1% of profit of All Registered Pharmaceutical to MOH for R&D Expenditure
This again makes the country the region's 7th most attractive market in Asia.
MUHAMMAD ALI 12

Pakistan Key Numbers (2017 Fact & Figures)
Top 100 Pharmaceuticals have 97% share of market value wise
Rest of 600 plus Pharmaceuticals contributes only 2.93% value wise
Top 100 Pharmaceuticals have 96% share of market unit wise
Rest of 600 plus Pharmaceuticals contributes only 4% unit wise
Top 100 Molecule have 61% of Market share
Rest of others Molecules contribute 39%
Top 100 Brands have 33% of Market share
Rest of others Brands contribute 67%
Top 10 Therapeutic class (ATC I) have 93 % share of market , rest 6 therapeutic class have 7% of share.
2017 New Launches contributes Pkr 2 billion
MUHAMMAD ALI 13

Country
TOTAL
PHARMACE
UTICAL
SALES
(USD
BILLION)
PHARMACE
UTICAL
SALES
(USD PER
CAPITA)
PHARMACE
UTICAL
SALES (% OF
HEALTH
EXPENDITU
RE)
PHARMACE
UTICAL
SALES
PRESCRITIO
N DRUGS
(USD
BILLION)
PHARMACE
UTICAL
SALES
OTC (USD
MILLION)
PHARMACE
UTICAL
SALES
ORIGINATO
R (USD
MILLION)
PHARMACE
UTICAL
SALES
GENERICS
(USD
MILLION)
Pakistan 2,29 12,40 34,20 1,70 0,59 0,22 1,48
India 15,63 12,10 16,10 13,36 2,27 1,38 11,88
Bangladesh 1,98 12,50 40,50 1,55 0,42 0,14 1,42
IFPMA Fact & Figures 2017
MUHAMMAD ALI 14

Pakistan Healthcare
Health expenditures: 2.6% of GDP (2014)
Physicians density: 0.81 physicians/1,000 population (2014)
Hospital bed density: 0.6 beds/1,000 population (2012)
Major infectious diseases:
Degree of risk: high
Food or waterborne diseases: bacterial diarrhea, hepatitis A and E, and typhoid fever
Vector borne diseases: dengue fever and malaria
Animal contact disease: rabies (2016)
MUHAMMAD ALI 15

What causes the most deaths?
MUHAMMAD ALI 16
The Institute for Health Metrics and Evaluation (IHME)

What causes the most premature death?
MUHAMMAD ALI 17

What health problems cause the most disability?
MUHAMMAD ALI 18

What causes the most death and disability combined?
MUHAMMAD ALI 19

Key Health Numbers, 2014 by IFPMA & WHO
Country
LIFE
EXPECTAN
CY AT
BIRTH
(YEARS)
LIFE
EXPECTAN
CY AT
AGE 60
(YEARS)
CHILD
MORTALIT
Y (PER
1,000
BIRTHS)
PHYSICIAN
S (PER
1,000
PEOPLE)
TOTAL
HEALTH
EXPENDIT
URE PER
CAPITA
(USD PER
CAPITA)
TOTAL
HEALTHCA
RE
EXPENDIT
URE
(%GDP)
PUBLIC
HEALTHCA
RE
EXPENDIT
URE
(%GDP)
OUT-OF-
POCKET
HEALTH
EXPENDIT
URE (% OF
PRIVATE
HEALTH
EXPENDIT
URE)
Pakistan 66,18 17,80 67,40 0,83 128,99 2,61 0,92 86,79
India 68,01 17,80 39,30 0,70 267,41 4,69 1,41 89,21
Bangladesh
71,63 18,80 32,10 0,36 88,08 2,82 0,79 92,89
MUHAMMAD ALI 20

Healthcare System Structure
MUHAMMAD ALI 21
Health Manpower 2013-2014 2014-2015 2015-2016
Hospitals 1,113 1,143 1,167
Dispensaries 5,413 5,548 5,695
Basic Health Units
Centers
5,571 5,438 5,464
Maternity & Child health
Centers
687 670 733
Rural Health Centers 667 669 675
TB Centers 329 334 339
Total Beds 118,378 118,170 118,869
Source: Ministry of Health, Planning Commission of Pakistan, Pakistan Bureau of Statistics

Healthcare System Structure
MUHAMMAD ALI 22
Hospitals
Dispensaries
Maternity & Child
welfare centers
Beds in hospitals
& dispensaries
etc.
Federal 9 83 3 2523
Punjab 368 1325 280 57648
Sindh 427 2912 221 33774
Khyber
Pakhtunkhwa/
FATA
270 915 131 21908
Baluchistan 127 567 96 7541
Sources:- i) Health Division ii) Provincial Health Directorates. 2016

Health systems by World health statistics 2015. WHO
Density of health workforce (per 10 000 population)
Country Physicians
Nursing and
midwifery
personnel
Dentistry
personnel
Psychiatrists Hospitals
Psychiatric
beds
Pakistan 8.3 5.7 0.6 <0.05 0.5 5.6
India 7.0 17.1 1.0 <0.05 -- 2.1
Bangladesh 3.6 2.2 0.3 <0.05 0.2 3.5
MUHAMMAD ALI 23

Healthcare Workforce
MUHAMMAD ALI 24
Health Manpower 2013-2014 2014-2015 2015-2016
Registered Doctors 167,759 175,223 184,711
Registered Dentists 13,716 15,106 16,652
Registered Nurses 86,183 90,276 94,766
Registered Midwives 32,677 33,687 34,668
Registered Lady Health
Visitor
14,388 15,325 16,448
Pakistan Bureau of Statistics

STATISTICS
TOTAL NUMBER OF DOCTORS / DENTAL SURGEONS (G.P's with basic degree only)
TOTAL NUMBER OF DOCTORS/DENTAL
SURGEONS REGISTERED
REGISTERED UP TO 31st DECEMBER, 2016
Up to 31st DECEMBER, 2016 AS
SPECIALISTS
M.B.B.S. B.D.S. L.S.M.F. M.B.B.S. B.D.S.
Province Total Total Total Total Total
Punjab/Federal Area 67486 7157 565 19015 731
Sindh 60315 6055 306 10996 450
K.P.K 19751 2626 54 5283 349
Baluchistan 4481 470 55 1290 49
A.J.K. 3229 331 4 879 38
Foreign Nationals 3812 486 106 110 4
Total 159074 17125 1090 37573 1621
TOTAL=159074+17125+1090= 177289
TOTAL LSMF=1090
TOTAL RMPs (Basic & Specialists)=(159074+37573)=196647
TOTAL RDPs (Basic & Specialists)=(17125+1621)=18746
GRAND TOTAL=196647+18746+1090=216483
GRAND TOTAL=RMP+RDP+LSMF
http://www.pmdc.org.pk/Statistics/tabid/103/Default.aspx

Doctor Universe Pakistan
General Practitioner , 27000
Physician, 4250
Pediatrcian, 2800
Cardiologict, 1200
Gynaecologist, 5000
Orthopaedician, 1000 Surgeon, 3000
MUHAMMAD ALI 26
Estimated Doctor Universe >65,000 Estimated Chemist Universe >45,000

Manufacturers & Importers
Distributors
89.97 %
Govt
Institutional
6.71%
Export 2.26%
Direct to
Doctors .77%
Direct to
patients .17%
Others .12%
Retail Pharmacies
59.25%
Wholsellers
29.16%
Doctors 3.75%
Private hospitals
2.60%
Others 3.45%
Govt Hospitals
1.79%
Channels of Distribution
MUHAMMAD ALI 27

Wholesale, Distributors & Pharmacies Universe
MUHAMMAD ALI 28
ENTIRE COUNTRY
Total Wholesale 4,443
Total Distributors 1,045
Normal Pharmacies 47,139
Private Hospital Pharmacies & Vicinity Pharmacies 11,222
Total Pharmacies 58,541

4 Year Total Pharmaceutical Market
MUHAMMAD ALI 29
Therapeutic Class Value in Pkr
Growth
(%)
2017 343,936,385,875 6.14
2016 324,042,332,978 15.64
2015 280,218,511,653 13.37
2014 247,164,343,362 11.72

Pakistan Pharmaceutical Growth Trend
MUHAMMAD ALI 30
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
2014 2015 2016 2017 2018

MNC vs National
MUHAMMAD ALI 31
Value Unit Growth Share
SELECTED TOTAL 343,936,385,875 2,604,859,276 6.14 100.00
NATIONAL 230,926,595,115 1,697,926,063 7.67 67.14
MULTI-NATIONAL 113,009,790,760 906,933,213 3.14 32.86

Leading Pharmaceutical Companies in Pakistan (Value Wise)
No. Name of the Manufacturer Value in Pkr Growth % Contribution %
Total 343,936,385,875 6.14 100.00
1 GLAXOSMITHKLINE 25,425,036,049 2.00 7.39
2 ABBOTT LAB PAK LTD 21,632,085,556 9.80 6.29
3 GETZ PHARMA 21,426,456,299 12.44 6.23
4 SAMI 18,028,510,063 9.03 5.24
5 MARTIN DOW LIMITED 14,280,245,205 13.33 4.15
6 THE SEARLE COMPANY 12,711,429,200 10.07 3.70
7 SANOFI-AVENTIS PAK 10,651,356,774 -2.06 3.10
8 OBS 10,263,419,074 1.33 2.98
9 GSK CONSUMER 10,237,998,715 14.80 2.98
10 HILTON 10,129,279,248 7.11 2.95
11 HIGH-Q INTL 9,831,053,211 24.35 2.86
12 BOSCH 9,597,149,040 8.84 2.79
13 PFIZER INC 9,218,802,077 3.70 2.68
14 NOVARTIS PH.PAK LT 9,133,307,529 -2.79 2.66
15 BARRETT HODGSON 7,031,661,852 10.05 2.04
16 ATCO 6,302,664,054 8.75 1.83
17 BAYER PAK PVT LTD 6,012,092,180 15.58 1.75
18 NESTLE PAKISTAN LT 5,690,343,085 -2.96 1.65
19 HIGHNOON 5,666,460,293 15.65 1.65
20 PHARMEVO PVT. LTD. 5,524,056,416 29.87 1.61

Leading Pharmaceutical Companies in Pakistan (Unit Wise)
No. Name of the Manufacturer Unit or Volume Growth % Contribution %
TOTAL 2,604,859,276 2.53 100.00
1 GLAXOSMITHKLINE 334,661,875 -4.98 12.85
2 ABBOTT LAB PAK LTD 188,944,872 7.25 7.25
3 SAMI 132,876,531 5.06 5.10
4 THE SEARLE COMPANY 114,619,830 10.23 4.40
5 MARTIN DOW LIMITED 105,285,359 3.12 4.04
6 GSK CONSUMER 101,437,395 7.56 3.89
7 GETZ PHARMA 100,922,328 10.68 3.87
8 BOSCH 75,315,211 6.20 2.89
9 SANOFI-AVENTIS PAK 73,877,666 -5.65 2.84
10 BARRETT HODGSON 69,851,136 6.90 2.68
11 ATCO 68,774,862 6.06 2.64
12 OBS 58,945,905 4.94 2.26
13 I.C.I 55,718,137 -16.32 2.14
14 HIGHNOON 47,228,536 11.78 1.81
15 HIGH-Q INTL 46,883,813 23.63 1.80
16 PFIZER INC 41,625,402 0.75 1.60
17 NABIQASIM 38,487,643 2.63 1.48
18 NOVARTIS PH.PAK LT 37,541,000 -10.88 1.44
19 HILTON 37,490,043 4.77 1.44
20 NESTLE PAKISTAN LT 30,763,677 -2.02 1.18

Leading Pharmaceutical Companies (New Launches Wise)
No. Name of the Manufacturer Value No of Products PPY
1 MACTER 245,027,604 2 122,513,802
2 THE SEARLE COMPANY 137,796,214 12 11,483,018
3 SAMI 128,374,514 4 32,093,629
4 HIGH-Q INTL 121,440,288 5 24,288,058
5 OBS 119,516,048 14 8,536,861
6 GETZ PHARMA 115,577,411 6 19,262,902
7 ATCO 110,877,596 8 13,859,700
8 CCL 103,749,303 8 12,968,663
9 WILSHIRE 71,311,275 2 35,655,638
10 FEROZSONS 67,739,275 2 33,869,638
11 WILSONS 55,870,085 2 27,935,043
12 GENIX PHARMA 55,488,435 9 6,165,382
13 PHARMEVO PVT. LTD. 44,449,950 3 14,816,650
14 I.C.I 41,325,921 4 10,331,480
15 ASIAN CONTINENTAL 39,913,533 3 13,304,511
16 FYNK PHARMA 38,495,524 1 38,495,524
17 S.J.& G. FAZUL 35,846,165 3 11,948,722
18 HIGHNOON 33,355,324 6 5,559,221
19 TABROS PHARMA 32,649,529 6 5,441,588
20 SCILIFE 27,080,321 5 5,416,064

0
50,000,000
100,000,000
150,000,000
200,000,000
250,000,000
300,000,000
Leading Pharmaceutical Companies (New Launches Wise)
Value PPY

Therapeutic Categories in Pakistan
No. Therapeutic Class Value in Pkr
Growth
(%)
Share
(%)
1 ALIMENTARY T.& METABOLISM 81,767,949,980 12.25 23.77
2 SYSTEMIC ANTI-INFECTIVES 75,516,779,937 -0.43 21.96
3 NERVOUS SYSTEM 31,518,438,716 12.07 9.16
4 CARDIOVASCULAR SYSTEM 25,620,352,283 10.94 7.45
5 MUSCULO-SKELETAL SYSTEM 25,108,143,417 8.75 7.30
6 RESPIRATORY SYSTEM 24,699,344,924 3.37 7.18
7 VARIOUS 20,890,548,241 1.40 6.07
8 DERMATOLOGICALS 12,352,518,001 13.26 3.59
9 BLOOD + B.FORMING ORGANS 12,068,777,766 4.17 3.51
10 G.U.SYSTEM & SEX HORMONES 10,629,827,853 12.27 3.09
11 SENSORY ORGANS 6,614,460,812 11.78 1.92
12 PARASITOLOGY 6,610,900,640 -1.65 1.92
13 ANTINEOPLAST+IMMUNOMODUL 3,423,773,439 -32.66 1.00
14 HOSPITAL SOLUTIONS 3,135,839,799 4.97 0.91
15 SYSTEMIC HORMONES 2,978,745,067 0.51 0.87
16 DIAGNOSTIC AGENTS 999,985,000 8.65 0.29

Therapeutic Categories In Pakistan And Their Share
ALIMENTARY T.& METABOLISM
24%
SYSTEMIC ANTI-INFECTIVES
22%
NERVOUS SYSTEM
9%
CARDIOVASCULAR SYSTEM
7%
MUSCULO-SKELETAL SYSTEM
7%
RESPIRATORY SYSTEM
7%
VARIOUS
6%
DERMATOLOGICALS
4%
BLOOD + B.FORMING ORGANS
4%
G.U.SYSTEM & SEX HORMONES
3%
SENSORY ORGANS
2%
PARASITOLOGY
2%
ANTINEOPLAST+IMMUNOMODUL
1%
HOSPITAL
SOLUTIONS
1%
SYSTEMIC HORMONES
1%
DIAGNOSTIC AGENTS
0%

Leading Molecules in Pakistan
No. Molecules Value in Pkr Growth % CAGR 2014-2017
1 INFANT MILKS 13,940,658,729 1.11 10.16
2 CEFTRIAXONE 9,595,679,508 11.22 14.43
3 CEFIXIME 8,574,109,236 7.78 16.62
4 OMEPRAZOLE 7,950,031,734 16.13 16.92
5 DICLOFENAC 7,277,816,466 6.86 8.97
6 CIPROFLOXACIN 7,097,912,357 2.64 8.97
7 AMOXICILLIN+CLAVULANIC ACID 7,054,405,361 0.25 10.46
8 PARACETAMOL 6,362,712,317 16.56 20.37
9 ESOMEPRAZOLE 5,499,717,093 9.95 18.84
10 MECOBALAMIN 4,018,438,906 8.03 14.16
11 SOFOSBUVIR 3,891,598,034 -36.58 0.00
12 INSULIN HUMAN BASE+INSULIN HUMAN ISOPHANE 3,685,471,615 16.42 16.57
13 METFORMIN+SITAGLIPTIN 3,483,509,162 33.15 42.64
14 CLARITHROMYCIN 3,326,539,051 -0.10 8.30
15 IBUPROFEN 3,112,913,973 12.87 8.67
16 GLIMEPIRIDE 3,068,597,145 14.17 14.21
17 CEFRADINE 2,985,190,859 -1.13 6.76
18 LEVOFLOXACIN 2,907,081,128 -4.74 7.49
19 MONTELUKAST 2,809,991,536 0.86 11.06
20 MOXIFLOXACIN 2,684,500,675 9.65 14.34

Leading Brands in Pakistan
No. Brand Name Manufacturer Generic Name Value in Pkr Growth %
1 AUGMENTIN GSK AMOXICILLIN+CLAVULANIC ACID 4,609,999,200 -0.05
2 PANADOL GSK PARACETAMOL 3,793,142,822 26.51
3 RISEK Getz OMEPRAZOLE 3,758,533,323 22.41
4 BRUFEN Abbott IBUPROFEN 2,774,684,794 14.41
5 NOVIDAT Sami CIPROFLOXACIN 2,597,536,484 4.26
6 OXIDIL Sami CEFTRIAXONE 2,462,408,965 2.88
7 CAC 1000 PLUS GSK ASCORBIC ACID+CALCIUM+COLECALCIFEROL+NICOTINAMIDE+PYRIDOXINE 2,404,945,096 34.69
8 HUMULIN 70/30 Eli Lilly INSULIN HUMAN BASE+INSULIN HUMAN ISOPHANE 2,330,393,062 14.19
9 VELOSEF GSK CEFRADINE 2,245,630,206 -0.24
10 METHYCOBAL Hilton MECOBALAMIN 2,126,372,891 5.88
11 FLAGYL Sanofi Aventis METRONIDAZOLE 1,970,680,577 -0.48
12 CEFSPAN Barrett CEFIXIME 1,772,118,653 10.71
13 AMOXIL GSK AMOXICILLIN 1,704,372,279 -6.76
14 ARINAC Abbott IBUPROFEN+PSEUDOEPHEDRINE 1,628,603,753 19.77
15 CALAMOX Bosch AMOXICILLIN+CLAVULANIC ACID 1,608,638,157 1.92
16 GETRYL Getz GLIMEPIRIDE 1,553,816,395 18.20
17 LACTOGEN 1 Nestle INFANT MILKS 1,552,140,718 6.48
18 NEXUM Getz ESOMEPRAZOLE 1,505,715,509 14.50
19 BETNOVATE N GSK BETAMETHASONE+NEOMYCIN 1,466,594,311 28.42
20 SURBEX Z Abbott
ASCORBIC ACID+CYANOCOBALAMIN+FOLIC
ACID+NICOTINAMIDE+PANTOTHENIC ACID+PYRIDOXINE+RIBOFLAVI 1,411,206,137 15.71

Area-wise Sales Performance of the
Pakistan Retail Pharmaceutical Market
MUHAMMAD ALI 40
South
Central
North
Quetta

The Product
The Product Pharmaceutical products are used in the treatment of diseases hence called “Drug”
Every operation pertaining to the drugs including import, manufacturing & distribution is
governed by “The Drugs Act 1976”.
The Product Drugs are manufactured under the strict quality standards called GMP (good
manufacturing practices)
No product can be marketed/distributed unless registered by the Ministry of Health, Pakistan
MUHAMMAD ALI 41

The Price
The key factor affecting the price of drugs include but not limited to
Uniqueness (availability) of the product
The country from where final dosage form or the main raw materials are imported
Process steps involved in manufacturing
Size of production (economies of scale)
MUHAMMAD ALI 42

The Price
Price structure Cost of raw/packaging materials
Cost of conversion
Cost of distribution
• Distributor margin
• Retailer margin
Cost of promotion
The cost of drugs is higher than the profits associated with them
MUHAMMAD ALI 43

Mark Up Components Of Drug Pricing Policy 2015
MUHAMMAD ALI 44
MRP to be applied Pack size
TP 15% Less
DP 8% Less
Manufacturing Cost - COGS 30%
Product Development & Stability 3%
Product Expiry 2%
Warehouse and Cold Chain 2%
Salesman salaries and travel 10%
Sales Promotion 3%
Samples 3%
General Administration 4%
Financial Charges 3%
WPPF & CRF 1%
Income Tax 8%
Distribution exp. & Discount 16%
Manufacturer Profit 15%
Total 100%

Major Trading Partners of Pakistan in
Pharmaceutical Products
Major Import Counties
 India
 China
 European Countries (Denmark, Switzerland, Germany, Belgium, Italy, Sweden )
Major Export Regions
 Afghanistan, Sri Lanka
 ASEAN Countries (Vietnam, Philippines, Laos, Cambodia, Myanmar)
 CIS Countries (Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan and Uzbekistan)
 African Countries (Burundi, Cote d'Ivoire, Ethiopia, Ghana, Kenya, Malawi, Rwanda, Senegal, Somalia,
Sudan, Uganda)
MUHAMMAD ALI 45

Country
PHARMACEUTICAL
EXPORTS
(US$MM)
PHARMACEUTICAL
IMPORTS
(US$MM)
NUMBER OF
EMPLOYEES
WAGES AND
SALARIES
(US$MM)
GROSS VALUE
ADDED
(US$MM)
Pakistan 184,54 712,71 36.336,00 316,39 1.223,50
India 11.333,18 1.487,41 587.468,59 3.441,70 17.766,44
Bangladesh 111,06 219,28 12.056,32 153,86 599,66
IFPMA Fact & Figures 2017
MUHAMMAD ALI 46

Pakistan vs. Indian Pharma
MUHAMMAD ALI 47
http://www.pharmabureau.org/about-2/stats-facts/

New Achievements of Pakistani Pharma
Pacific Pharma got MHRA Approved Plant.
Getz Pharma got WHO qualification for their Plant.
Martin Dow acquired 2 pharmaceutical manufacturing facility in France.
MUHAMMAD ALI 48

References
Pakistan Demography Profile from World fact book
Quintiles IMS Institute (Q4, 2017)
Healthcare System Structure data obtained from
 PMDC website
 i) Health Division. ii) Provincial Health Directorates.
IFPMA Fact & Figures 2017
WHO World Health Statistics 2015 & 2016
Health and Nutrition - Ministry of Finance 2016
The Institute for Health Metrics and Evaluation (IHME) (Pakistan Profile)
MUHAMMAD ALI 49

Presentation
For further presentation related to pharmaceutical sales and marketing visit my blog
www.phrali.blogspot.com
Some of my presentation are
 How to make Marketing Plan for Pharmaceutical Product
 Pharmaceuticals Marketing Strategies
 Pharmaceutical Sales in Pakistan
 Marketing and Sales roles in the pharmaceutical industry
 New Launch Strategy & Product Cycle
 Role of Business Development in Pharmaceuticals (Generic Market)
MUHAMMAD ALI 50

Pakistan Pharmaceutical Market Overview 2017

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Pakistan Pharmaceutical Market Overview 2017

Similar to Pakistan Pharmaceutical Market Overview 2017 (20)

More from Muhammad Ali Jehangir

More from Muhammad Ali Jehangir (20)

Recently uploaded

Recently uploaded (20)

Pakistan Pharmaceutical Market Overview 2017